九典制药 (300705)
Hunan Jiudian Pharmaceutical Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 50021.25
- Circulating A-Shares(W): 36979.13
- Earnings Per Share(RMB): 0.8200
- Net Assets Per Share(RMB): 5.2688
- Operating Revenue(W RMB): 226803.73
- Total Profit(W RMB): 45267.93
- Net Profit Attributable to Parent(W RMB): 40636.25
- Net Profit Growth Rate(%): -9.64
- Weighted Return on Equity(%): 14.8500
- Operating Cash Flow Per Share(RMB): 0.9110
- Undistributed Profit Per Share(RMB): 2.9995
- Capital Reserve Per Share(RMB): 1.1275
2. Main Business
The main business covers:
- Chemical Drug Preparations
- Active Pharmaceutical Ingredients (API)
- Pharmaceutical Excipients
- Traditional Chinese Medicine
- Health Products
3. Company Basic Information
- Company Name: Hunan Jiudian Pharmaceutical Co., Ltd.
- Listing Date: 2017-10-10
- Industry: Pharmaceutical Manufacturing
- Address: Building A1, Jinrui Lugu Technology Park, Lutian Road, Changsha High-tech Development Zone, Hunan Province
- Website: www.hnjiudian.com
- Company Profile: The company's predecessor was Hunan Weikang Pharmaceutical Co., Ltd., founded on January 19, 2001. It was renamed Hunan Jiudian Pharmaceutical Co., Ltd. in 2003. In December 2014, it was restructured into a joint-stock company.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 494.33 | 1.34 |
| 2 | Guotai Dual-Bond Securities Investment Fund Class A | Fund | 290.00 | 0.78 |
| 3 | Southern China Securities 1000 ETF | Fund | 274.79 | 0.74 |
| 4 | Huayu Investment Co., Ltd. | General Legal Person | 229.00 | 0.62 |
| 5 | Anxin Pharmaceutical Health Theme Equity Fund Class A | Fund | 203.13 | 0.55 |
5. Concept Sectors
- Convertible Bonds
- CXO Concept
- Helicobacter Pylori
- Hepatitis Concept
- Innovative Drugs
- High-Performance Stocks
- Exclusive Fund Holdings
- Share Buyback Plan
- Special Loans
- ChiNext 300
- SZSE Innovation
- ChiNext Innovation
- ChiNext Quality
- ChiNext Pharmaceuticals
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information